In The Wall Street Transcript William Blair’s Matt Phipps shares his outlook on what biotech industry companies he’s most closely monitoring for 2022 and the factors at play influencing his perspective sectorwide.
Equity Research
Matt Phipps Discusses Biotech Stocks With The Wall Street Transcript
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
KKR Has Acquired a Majority Stake in Agiloft
William Blair served as exclusive financial advisor to KKR in connection with its acquisition of a majority stake in Agiloft, a portfolio company of FTV Capital (FTV).
Read moreVaricent Has Agreed to Receive a Strategic Investment Led by Warburg Pincus
William Blair acted as financial advisor to Varicent, a portfolio company of Great Hill Partners and Spectrum Equity, in connection with its pending strategic investment led by Warburg Pincus, LLC, alongside existing investor Great Hill Partners, with participation from Spectrum Equity and company management.
Read moreSensio Has Agreed to be Acquired by Nordic Capital
William Blair acted as the exclusive financial advisor to Sensio, a portfolio company of Longship, in connection with its pending sale to Nordic Capital.
Read more